Benefits
Acute diarrhea treatment 1143-pt RCT (Greuter 2020 PMC7326027)
Greuter T et al. 2020 (Front Med 7:276, PMC7326027) — analysis of 4 unpublished SF68 studies. Treatment RCT (n=1143): SF68 TID for 7 days REDUCED time to resolution of diarrhea (median 3 vs 4 days, P<0.001). Time to resolution of secondary symptoms also significantly reduced. Foundational large-scale acute diarrhea evidence.
AAD prevention 1397-pt RCT (Greuter 2020)
Greuter 2020 prevention RCT (n=1397): SF68 BID for 7 days during antibiotic therapy. AAD development 8.6% SF68 vs 16.2% placebo (P<0.001) = ~47% absolute risk reduction. Open-label study (n=4340) consistent with RCT findings. Foundational AAD prevention evidence.
Licensed pharmaceutical Austria/Italy/Switzerland
SF68® (BIOFLORIN) is LICENSED PHARMACEUTICAL in AUSTRIA, ITALY, SWITZERLAND for: (i) acute infectious enteritis treatment (children + adults); (ii) traveler's diarrhea; (iii) AAD prevention + treatment. Distinguishing pharmaceutical regulatory status rare among probiotic supplements (joins B. clausii Enterogermina, EcN Mutaflor, CBM588 MIYA-BM in this category).
Cochrane Review 4-RCT inclusion (n=333)
Cochrane Review on probiotic treatment of acute infectious diarrhea included 4 SF68 RCTs (n=333) demonstrating REDUCED RISK for diarrhea lasting 4 days or longer. HONEST limitation: trial quality assessed as insufficient with unclear/inadequate allocation concealment + no blinding in some + no/unclear intention-to-treat analyses. Important methodological caveat balanced against clinical use record.
Arginine deiminase NF-κB + JNK(AP-1) inhibition
Mechanism: E. faecium SF68 ARGININE DEIMINASE inhibits host cell NF-κB + JNK(AP-1) pathway activation responsible for anti-inflammatory + immunomodulatory effects (Gut Microbes 2022, doi:10.1080/19490976.2022.2106105). Foundational mechanism for intestinal inflammation modulation.
Safety profile (1.1-1.4% AE in RCTs)
Greuter 2020: AE incidence 1.1-1.4% in RCTs; 4.7-7.4% in open-label studies. Discontinuation due to intolerability MORE FREQUENT in placebo group (0.7% vs 0.1%, NS). Foundational large-scale safety evidence.
HONEST counter-evidence (animal infection studies)
HONEST framing: some in vivo animal studies report NO significant beneficial effects or even ADVERSE EFFECTS — including HIGHER bacterial loads + shedding of enteric pathogens (Salmonella Typhimurium) in some animal infection models. Important counter-evidence context — generalizability to human populations remains under investigation. Position as licensed-pharmaceutical-evidence supported in humans but with animal model nuance.
Mechanism of action
Arginine deiminase NF-κB + JNK(AP-1) inhibition
Gut Microbes 2022 mechanism — SF68 arginine deiminase responsible for anti-inflammatory + immunomodulatory effects. Inhibits host cell NF-κB + JNK(AP-1) pathway activation. Distinguishing biochemical mechanism among probiotics.
Time-to-resolution acceleration
Greuter 2020: SF68 TID for 7 days REDUCES median time to resolution of acute diarrhea by 1 day vs control (3 vs 4 days, P<0.001). Mechanism: gut microbiota normalization + epithelial barrier support.
AAD prevention via competitive exclusion
BID dosing during antibiotic therapy reduces AAD by ~47% absolute. Mechanism: competitive exclusion of pathogenic flora during antibiotic-induced dysbiosis. Foundation prevention mechanism.
Acid + bile resistance
SF68 survives gastric acidity + bile salts — efficient delivery to intestine. Mechanism: viable probiotic delivery without specialized formulation.
Intestinal inflammation mitigation
Mitigates symptoms of human + animal intestinal inflammation. Mechanism via arginine deiminase pathway inhibition. Distinguishing among Enterococcus species.
Enterococcus species safety considerations
Enterococcus species generally raise vancomycin-resistance concerns — but SF68 specifically has favorable safety profile in human licensed-pharmaceutical use record. Distinguishing strain-specific safety vs species-level concerns.
Clinical trials
Randomized double-blind placebo-controlled trial (Greuter T et al. 2020, Front Med 7:276, PMC7326027, doi:10.3389/fmed.2020.00276). One of 4 analyzed unpublished SF68 studies.
1143 patients with acute diarrhea. SF68 TID for 7 days vs placebo. Primary endpoint: time to resolution of diarrhea.
Treatment RCT met primary endpoint: median time to resolution 3 vs 4 days (P<0.001). Time to resolution of secondary symptoms also significantly reduced. AE incidence 1.1-1.4%. Foundational large-scale acute diarrhea treatment evidence supporting Austrian/Italian/Swiss pharmaceutical licensing.
Randomized placebo-controlled trial (Greuter T et al. 2020, Front Med 7:276, PMC7326027). One of 4 analyzed unpublished SF68 studies.
1397 patients on antibiotic therapy. SF68 BID for 7 days vs placebo. Primary endpoint: percentage of AAD development.
AAD development 8.6% SF68 vs 16.2% placebo (P<0.001) = ~47% absolute risk reduction. Open-label study (n=4340) consistent with RCT findings. Foundational AAD prevention evidence.
Cochrane Review on probiotic treatment of acute infectious diarrhea.
4 RCTs of SF68 included (n=333 total). Acute infectious diarrhea population.
Demonstrated REDUCED RISK for diarrhea lasting 4 days or longer. HONEST limitation: trial quality insufficient with unclear/inadequate allocation concealment + no blinding in some trials + no/unclear intention-to-treat analyses. Important methodological caveat balanced against clinical use record.
About this ingredient
ENTEROCOCCUS FAECIUM SF68® (BIOFLORIN, Cerbios-Pharma) is a LICENSED PHARMACEUTICAL probiotic in AUSTRIA, ITALY, SWITZERLAND for: (i) acute infectious enteritis treatment in children + adults; (ii) traveler's diarrhea; (iii) AAD prevention + treatment. Joins B. clausii (Enterogermina), E. coli Nissle 1917 (Mutaflor), CBM588 (MIYA-BM) in licensed-pharmaceutical probiotic category — distinguishing regulatory status rare among probiotic supplements. PIVOTAL CLINICAL EVIDENCE: GREUTER T et al. 2020 PMC7326027 (Front Med 7:276, doi:10.3389/fmed.2020.00276) — analysis of 4 unpublished SF68 studies. TREATMENT RCT (n=1143): SF68 TID for 7 days REDUCED time to resolution of diarrhea (median 3 vs 4 days, P<0.001) + time to resolution of secondary symptoms also significantly reduced. AAD PREVENTION RCT (n=1397): SF68 BID for 7 days during antibiotic therapy → AAD development 8.6% vs 16.2% placebo (P<0.001 = ~47% absolute risk reduction). OPEN-LABEL study (n=4340) consistent with RCT findings. AE incidence 1.1-1.4% in RCTs; 4.7-7.4% in open-label studies. Discontinuation due to intolerability MORE FREQUENT in placebo (0.7% vs 0.1%, NS). COCHRANE REVIEW on probiotic treatment of acute infectious diarrhea included 4 SF68 RCTs (n=333) demonstrating REDUCED RISK for diarrhea ≥4 days — HONEST limitation: trial quality assessed as insufficient with unclear/inadequate allocation concealment + no blinding in some + no/unclear intention-to-treat analyses. ARGININE DEIMINASE MECHANISM (Gut Microbes 2022, doi:10.1080/19490976.2022.2106105) — SF68 arginine deiminase inhibits host cell NF-κB + JNK(AP-1) pathway activation responsible for anti-inflammatory + immunomodulatory effects.
MECHANISMS: ARGININE DEIMINASE NF-κB + JNK(AP-1) INHIBITION (distinguishing biochemical mechanism); TIME-TO-RESOLUTION acceleration (Greuter 2020 1-day median reduction); AAD PREVENTION via competitive exclusion (47% absolute risk reduction); ACID + BILE RESISTANCE (efficient delivery without specialized formulation); INTESTINAL INFLAMMATION MITIGATION (arginine deiminase pathway). EVIDENCE: 3/5 reflects: (1) GREUTER 2020 PIVOTAL 1143-pt acute diarrhea TREATMENT RCT, (2) GREUTER 2020 PIVOTAL 1397-pt AAD PREVENTION RCT (47% absolute risk reduction), (3) COCHRANE REVIEW 4-RCT inclusion with reduced ≥4-day diarrhea risk, (4) ARGININE DEIMINASE biochemical mechanism evidence, (5) AUSTRIAN/ITALIAN/SWISS LICENSED PHARMACEUTICAL regulatory status, (6) HONEST METHODOLOGICAL CAVEATS — Cochrane assessed trial quality as insufficient (unclear allocation, no blinding, ITT issues), (7) HONEST COUNTER-EVIDENCE — animal infection studies report no benefit or adverse effects (higher bacterial loads, Salmonella Typhimurium shedding) in some models, (8) ENTEROCOCCUS SPECIES safety considerations — vancomycin-resistance concerns mitigated by SF68 specific human use record, (9) industry context (Cerbios-Pharma Bioflorin) — important but multi-RCT methodology, (10) higher-evidence than typical 'enterococcus probiotic' due to large RCT sample sizes + pharmaceutical licensing in 3 European countries. SAFETY: Excellent in humans — extensive licensed pharmaceutical use record + favorable AE profile. Best positioned as: (a) ACUTE DIARRHEA TREATMENT (Greuter 2020 1143-pt RCT — TID dosing 7 days), (b) AAD PREVENTION concurrent with antibiotic therapy (Greuter 2020 1397-pt RCT — BID dosing 7 days), (c) TRAVELER'S DIARRHEA (licensed indication), (d) ACUTE INFECTIOUS ENTERITIS in children + adults (licensed indication), (e) BIOFLORIN branded preparation (Cerbios-Pharma) preferable for clinical evidence-matched formulation, (f) PREGNANCY: limited specific data, (g) IMMUNOCOMPROMISED: caution due to Enterococcus species vancomycin-resistance considerations (mitigated by SF68 specific human safety record), (h) ANTIBIOTIC USE: COMPATIBLE — designed for concurrent dosing during antibiotic therapy, (i) LICENSED PHARMACEUTICAL status distinguishing — joins B. clausii Enterogermina + EcN Mutaflor + CBM588 MIYA-BM category. Honest framing: SF68 is among the BEST-EVIDENCED licensed pharmaceutical probiotics — Greuter 2020 large RCT sample sizes (1143 + 1397 patients) demonstrate clinically meaningful effects on acute diarrhea + AAD prevention.
CRITICAL HONEST LIMITATIONS: (1) Cochrane Review assessed trial quality as INSUFFICIENT (unclear allocation concealment, no blinding in some, ITT issues), (2) Greuter 2020 analysis based on UNPUBLISHED studies (4 studies analyzed), (3) ENTEROCOCCUS SPECIES vancomycin-resistance concerns mitigated but not eliminated by SF68 specific human safety record, (4) animal infection studies show conflicting results (Salmonella Typhimurium shedding in some models). Despite caveats, AUSTRIAN/ITALIAN/SWISS pharmaceutical licensing supports clinical use — distinguishing regulatory status. Cerbios-Pharma Bioflorin industry context warrants caveat. Reasonable acute diarrhea + AAD prevention adjunct based on large-scale RCT evidence + 3-country pharmaceutical licensing — particularly compelling for hospitalized patients on antibiotics or those with recurrent diarrhea seeking probiotic with documented arginine deiminase mechanism.